Although the impact of tumor immunology on the clinical management of most cancers is still negligible, there is increasing evidence that anticancer immune responses may contribute to the control of cancer after conventional chemotherapy. Thus, radiotherapy and some chemotherapeutic agents, in particular anthracyclines, can induce specific immune responses that result either in immunogenic cancer cell death or in immunostimulatory side effects. This anticancer immune response then helps to eliminate residual cancer cells (those that fail to be killed by chemotherapy) or maintains micrometastases in a stage of dormancy. Based on these premises, in this Review we address the question, How may it be possible to ameliorate conventional therapies by stimulating the anticancer immune response? Moreover, we discuss the rationale of clinical trials to evaluate and eventually increase the contribution of antitumor immune responses to the therapeutic management of neoplasia.

Find the latest version:

http://jci.me/35180-pdf
The anticancer immune response: indispensable for therapeutic success?

Laurence Zitvogel,1,2,3,4 Lionel Apetoh,1,3,4 François Ghiringhelli,1,2,3 Fabrice André,3 Antoine Tesnière,3,4,5 and Guido Kroemer3,4,5

1INSERM, U805, Villejuif, France. 2CIC BTS07, Villejuif, France. 3Institut Gustave Roussy, Villejuif, France. 4Faculté de Médecine, Université Paris-Sud 11, Kremlin-bicêtre, France. 5INSERM, U848, Villejuif, France.

Although the impact of tumor immunology on the clinical management of most cancers is still negligible, there is increasing evidence that anticancer immune responses may contribute to the control of cancer after conventional chemotherapy. Thus, radiotherapy and some chemotherapeutic agents, in particular anthracyclines, can induce specific immune responses that result either in immunogenic cancer cell death or in immunostimulatory side effects. This anticancer immune response then helps to eliminate residual cancer cells (those that fail to be killed by chemotherapy) or maintains micrometastases in a stage of dormancy. Based on these premises, in this Review we address the question, How may it be possible to ameliorate conventional therapies by stimulating the anticancer immune response? Moreover, we discuss the rationale of clinical trials to evaluate and eventually increase the contribution of antitumor immune responses to the therapeutic management of neoplasia.

A daunting diversity of distinct molecular etiologies gives rise to one class of life-threatening diseases — cancer (1) — which affects half of the inhabitants of developed countries during their lifetime and kills one-third of them. The changes in the cell biology of tumor cells are conditioned by epigenetic and genetic reprogramming, genomic instability being an essential feature of both oncogenesis and tumor progression. This epigenetic and genetic modification of cancer cells is often accompanied by the emission of “danger signals,” as well as the expression of ectopic or mutated proteins. Thus, the antigenic characteristics of tumor cells can be perceived by the innate and cognate immune systems. As defined primarily by Hanahan and Weinberg, the tumorigenic process stems from six hallmark criteria: i.e., growth signal self-sufficiency, resistance to growth-inhibitory signals, resistance to apoptosis, limitless growth potential, sustained angiogenesis, and metastasizing potential (1). A seventh potential hallmark of cancer, avoidance of immunosurveillance (2), allowing tumor cells to escape anticancer immune responses or to actively suppress them (2, 3), has come under close scrutiny. The question as to whether and to what extent immunosurveillance controls and shapes the development of human cancers has been examined in several recent reviews (4–6). There is increasing evidence that tumors develop more frequently in immunodeficient patients, for instance, in transplant recipients (7). This strongly suggests that at least part of the vast evidence in favor of an important role for immunosurveillance in oncogenesis and tumor progression, as obtained in mouse models, can be extrapolated to the human system.

Our ever-expanding understanding of the molecular and cellular etiology of cancer has not yet been accompanied by a parallel improvement in therapeutic outcome. The purpose of this review is to raise a series of related questions: Is the success (or the lack thereof) of anticancer chemotherapy or radiotherapy conditioned by contribution of the immune system? And, if so, is it possible to enhance conventional therapies by stimulating the anticancer immune response? How could we best design clinical trials to interrogate (and eventually increase) the contribution of antitumor immune responses to the therapeutic management of neoplastic disease?

Relationship between cancer and the immune system: a quick guide

As previously discussed in a recent review (4), the immune system may prevent tumor outgrowth. Thus, occult cancer becomes manifest in mice after ablation of T cells and/or injection of anti–IFN-γ antibodies, indicating that the adaptive immune response can keep cancer in check during the equilibrium state (6). However, cancer cells escape the innate and adaptive immune responses (immunosurveillance) by immunoselection (selection of nonimmunogenic tumor cell variants, also known as immunoediting) or immunosubversion (active suppression of the immune response).

Although the concept of immunoediting has been developed in mice, there is evidence that this idea may also apply to humans. Unstable microsatellite tumors in humans (which can be expected to carry more neoantigens than tumors with chromosomal instability) are prominently infiltrated by CTLs and are associated with a favorable prognosis (8–10). Tumor infiltration by T, NK, and NKT cells is a sign of improved prognosis in multiple human neoplasias, including melanoma (11), colon (12), and ovarian cancers (13). Spontaneous tumor regression coupled to massive lymphocyte infiltration has been noted in individual patients with basal cell carcinoma (14), Merkel cell carcinoma (15), and lung carcinoma (16). High levels of antibodies reactive against the tumor suppressor protein p53 have a positive prognostic value in ovarian (17) and gastric cancer (18). In patients with early breast cancer, survival is favorably influenced by a natural humoral immune response to mucin. Indeed, mucin MUC1, a heterodimeric transmembrane glycoprotein aberrantly overexpressed by most human

Nonstandard abbreviations used: ACT, adoptive cell transfer; ATM, ataxia telangiectasia mutated; CEA, carcinoembryonic antigen; CHK1, checkpoint kinase–1; CRT, calreticulin; 5-FU, 5-fluorouracil; HMGB1, high mobility group box 1 protein; IM, imatinib mesylate; KLH, keyhole limpet hemocyanin; NKG2D, NK cell group 2D; PSA, prostate-specific antigen; TRP-2, tyrosinase-related protein 2.

Conflict of interest: The authors have declared that no conflict of interest exists.

cancerous tumors, is a tumor antigen recognized by T cells and is shared by different tumors such as breast, colon, pancreas, ovary, and lung carcinoma and may be tumor specific due to its differential glycosylation in normal versus tumor cells (19). One important question concerns the impact of conventional anticancer chemotherapies on the relationship between the tumor and the immune system. Therapy that is applied during the tumor escape phase not only affects the tumor but also modulates the relationship between the tumor and the immune system. Thus, chemotherapy can, by simply reducing the tumor mass (debulking), reduce its immunosuppressive properties. As a proof of principle, the mere surgical removal of the primary tumor (mechanical debulking) can reverse tumor-induced immune tolerance, restoring the antibody- and cell-mediated immune responses, even in animals bearing metastatic breast cancer (20). By enforcing the selection of chemotherapy-resistant tumor cells and by inducing additional mutations (chemotherapy often involves mutagenic agents), therapy can induce the expression of new tumor antigens. Chemotherapy can cause immunogenic cancer cell stress or death and hence mediate a sort of cancer vaccination effect (as discussed below). Furthermore, chemotherapy can stimulate the immune system, either via a direct effect on immune effectors or regulatory mechanisms or indirectly, by causing lymphopenia followed by homeostatic proliferation of immune effectors that may be particularly active in the anticancer response. The combination of these effects may “reset” the relationship between the tumor and the immune system from the latest stage (escape) to a preceding state (elimination or equilibrium).
Immunostimulatory side effects of anticancer drugs

Although cytotoxic anticancer drugs as well as so-called targeted agents act mostly through direct effects on cancer cells, many among these agents have additional effects on the immune system that may contribute to their therapeutic efficacy (Figure 1).

Transient lymphopenia (abnormally low levels of blood lymphocytes) may activate homeostatic mechanisms that finally stimulate tumor-specific effector T cells. Thus, the therapeutic induction of lymphopenia has raised considerable interest in the context of adoptive cell transfer (ACT) therapies (which involve ex vivo generation of tumor-reactive lymphocytes from endogenous tumor infiltrating lymphocytes and their activation and expansion before reinfusion into the tumor-bearing host) and vaccination against melanoma (21). Animal studies demonstrated that lymphopaenia enhances the effectiveness of adoptively transferred tumor-specific CD8+ T cells (22). These experimental data have been tested in a clinical trial on 35 patients with metastatic melanoma refractory to conventional treatments. A highly lymphodepleting conditioning regimen was followed by ACT with tumor-infiltrating lymphocytes (TILs), resulting in 51% objective response rates associated with a persistent clonal lymphocytosis and/or antimelanocyte autoimmunity (23). In mice, lymphodepletion can be combined with vaccination strategies to promote the differentiation of central memory T cells specific for tumor antigens (24–27). The clinical relevance of these findings has been validated in a randomized clinical trial in myeloma (28). The in vivo–primed T cells of patients who were immunized with the 7-valent pneumococcal conjugate vaccine (PCV; Prevnar) were first collected following vaccination. Patients who then received high-dose chemotherapy and autologous stem cell transplantation as well as an infusion of these in vivo–primed and in vitro–expanded T cells, followed by subsequent booster immunizations, had a robust reconstitution of clinically relevant antimicrobial immunity within a month after transplantation (28). Defeating T cell fatigue after ACT against cancer or HIV has also been achieved with IL-15 (29), anti-CD40 (30), or programmed cell death 1 (PD-1) blockade (31). These findings suggest that, after some additional refinement, chemotherapy or irradiation-induced lymphodepletion, combined with additional manipulations such as ACT and immunopharmacological interventions, might achieve antitumor immune responses.

Hormonotherapy, the use of hormonal manipulation, is part of the clinical armamentarium for the management of breast and prostate cancer. The influence of androgens on lymphocyte development and activation has been reviewed (32). Experimental data indicate that androgen deprivation increases the number of naive T cells exported from the thymus and may therefore contribute to broadening the repertoire of T cell immunity, leading to effective antitumor immune responses and breaking of tumor-induced tolerance (33, 34). Moreover, androgen deprivation enhances the production of newly generated IgM+ naive B cells from bone marrow (35). Androgen ablation in prostate cancer patients may activate immune responses to some prostate tumor antigens by increasing the pool of naive T cells (as demonstrated by TCR rearrangement excision circle [TREC] analyses; TRECs are stable DNA circles excised from T cell germline DNA to allow for TCR formation during early T cell development and exist in high concentrations in thymic emigrants), decreasing and/or diluting the population of Tregs, and favoring the concomitant infiltration of T cells into tumor beds (36, 37). One study performed on 73 men bearing nonmetastatic prostate cancer and 50 controls showed that neoadjuvant hormonal and radiation therapy (but not radical prostatectomy) can elicit a tumor-specific autoantibody response (38). Humoral responses arose early and were durable in most cases, prompting the manipulation of B cell responses by immunotherapy.

Some agents (in particular cyclophosphamide but also fludarabine, gemcitabine, oxaliplatin, and 5-fluorouracil [5-FU]) can at least partially deplete or transiently inactivate tumor-protective Tregs (39–41). Several clinical trials have combined low doses of cyclophosphamide and antitumor vaccination for the treatment of metastatic melanoma, without any clear results, perhaps due to the lack of statistical power (42–46). In a small, randomized study performed on 42 metastatic breast cancer patients, cyclophosphamide was combined with a vaccine composed of a synthetic sialyl-Tn epitope linked to keyhole limpet hemocyanin (KLH) and an adjuvant. KLH is a natural protein isolated from the marine mollusk keyhole limpet and used as a carrier protein together with weak antigens to boost immune responses to hapten, self antigens, and idiotype proteins. A statistically significant increase in median survival from 12 months to 20 months was reported (47). A similar trend was observed in renal cell carcinoma patients immunized with allogeneic, mature DCs pulsed with tumor lysates and KLH and also receiving 300 mg/m2 i.v. cyclophosphamide 4 and 3 days before each monthly vaccination (48). In yet another study, 10 end-stage cancer patients received 1 daily dose of 100 mg cyclophosphamide, every other week, for 4 weeks (49). This “metronomic” (i.e., administered orally daily) cyclophosphamide treatment suppressed Treg inhibitory functions and restored the proliferative capacity of effector T cells as well as the cytotoxicity of NK cells (49, 50).

Many other anticancer agents also have immunostimulatory effects that have been demonstrated at the clinical level. For example, gemcitabine has been reported to enhance the frequency of IFN-γ-producing T cells and/or CD69+ activated cells in pancreatic cancer patients (51). In a phase I trial, gemcitabine elicited cellular immune responses in non–small cell lung cancers (52). One clinical trial examined the combined effects of gemcitabine and cytokines (GM-CSF and low doses of IL-2) in 42 patients presenting with advanced colorectal cancers. The objective responses rates and time to progression were encouraging and associated with increased tumor-specific CTL precursor frequencies in responders (53), prompting the initiation of a phase III trial. Another example is provided by a study of imatinib mesylate (IM; also known as STI571 and Gleevec), an inhibitor of the tyrosine kinases BCR-ABL, PDGFR, and KIT. Some patients with gastrointestinal stromal tumors (GISTs) that have no c-KIT mutation (and hence lack the IM target) responded to IM (54), suggesting that IM can exert indirect antitumor effects. Indeed, in a fraction of patients with GIST, IM causes an increase in NK activity. The activation of NK cells induced by IM constitutes a positive prognostic parameter (54), indicating that immunostimulation may contribute to the therapeutic effect of IM in patients, as has been suggested by animal experiments (55).

Immunogenic cancer cell stress and death

Transforming cells have to overcome both intrinsic (cell-autonomous) and extrinsic (immune-mediated) barriers to tumorigenesis. One important intrinsic barrier against transformation includes the activation of a DNA damage response after oncogenic stress, resulting in the activation of ataxia telangiectasia mutated (ATM), checkpoint kinase–1 (CHK1), and finally, p53-
dependent apoptosis (56) or senescence (57). As a result, prono-
eplastic lesions and in situ carcinomas often manifest the activa-
tion of ATM, CHK1, and p53, while advanced cancers suppress
or lose this DNA damage response. An extrinsic barrier against
tumor growth consists of the elimination of transforming cells by
bystander effects (3, 58). Thus, these barriers may be linked in molecular terms (3, 58). DNA damage response induces expression
of NK cell group 2D (NKG2D) ligands on tumor cells in an ATM-
and CHK1-dependent fashion (59). NKG2D is an activating
receptor involved in tumor immunosurveillance that is expressed
on NK, NK T, and γδ T cells and resting (in mice) and/or activated
(in humans) CD8+ T cells. The expression of NKG2D ligands
on the surface of transforming cells thus can be expected to play
a major role in tumor surveillance (Figure 1).

Although p53 is not required for the expression of NKG2D
ligands in cells undergoing DNA damage (59), a recent study high-
lights an important cooperation between p53-induced tumor cell
senescence and the innate immune system (57). Restoration of p53
function in established liver cancers led to tumor regression, but
only when the mice carried an intact immune system. Thus, the
reactivation of p53 led to the remission of liver cancer, an effect
that was lost after ablation of NK cells and macrophages (57).
These examples illustrate how molecules that are activated during
early tumorigenesis (e.g., ATM, CHK1, p53) can alert the immune
system to mediate an antitumor response. As chemotherapy with
dNA-damaging agents often activates ATM, CHK1, and p53, it
appears plausible, yet remains to be proven, that such agents also
elicit ATM-, CHK1-, and p53-dependent immune effects.

Chemotherapeutic agents and radiation can increase the
immunogenic properties of tumor cells by enhancing MHC class
I expression (60), thereby increasing their vulnerability to CTLs.
Similarly, some chemotherapeutic agents (such as genotoxic
agents and histone deacetylase inhibitors) increase the expression
of NKG2D ligands (59, 61), thus facilitating tumor cell lysis by
NKG2D-expressing lymphocytes (including NK cells, NKT cells,
and CTLs). Yet another frequent effect of DNA damage inflicted
by radiotherapy or chemotherapy is the increase in the expres-
sion of death receptors (in particular Fas/CD95 and TNF-relat-
ed apoptosis-inducing ligand [TRAIL] receptors) (62), enabling
lysis of the tumor cells by Fas/CD95 ligand and TRAIL-positive
immune effectors (Figure 1).

Tumor cell demise often occurs through apoptosis or necrosis.
Although there are teleological arguments to suggest that apop-
tosis must be nonimmunogenic or even tolerogenic (because phys-
iological cell death occurs through apoptosis but does not lead to
autoimmunity), and although necrosis (which is often pathologi-
cal) has been considered as being proinflammatory, the theoreti-
cal equations in which apoptosis equals nonimmunogenicity and
necrosis equals immunogenicity do not withstand experimental
verification. Instead, it seems that apoptosis is nonuniform in
biochemical terms, meaning that various pathways can lead to
cell death and induce stimulus-specific changes. Anthracyclines,
oxaliplatin, and ionizing irradiation have the exceptional capac-
ity to induce immunogenic cell death, while the vast majority of
chemotherapeutic agents induce nonimmunogenic cell death
(63–66). Anthracyclines, oxaliplatin, and ionizing irradiation also
have the particular ability to induce the early, preapoptotic trans-
location of the chaperone calreticulin (CRT) from the lumen of the
dendoplasmic reticulum (endo-CRT) to the plasma membrane
(ecto-CRT) (64, 65, 67). Ecto-CRT then facilitates the engulfment
of the tumor cell by DCs yet does not induce DC maturation. Neu-
ralization or knockout of CRT abolishes the immunogenicity
of tumor cell death, while exogenous supply of recombinant CRT
can restore the immunogenicity per se of nonimmunogenic cell
death (64, 65, 67) (Figure 1).

Another chaperone, HSP90, has recently been reported to be
involved in the immunogenicity of human myeloma cell death
elicted by the proteasome inhibitor bortezomib (68). In this in
vitro model, HSP90 is exposed on the plasma membrane surface
of myeloma cells following exposure to bortezomib and induces
the phenotypic maturation of DCs (Figure 1). Yet another factor
that acts on DCs is high mobility group box 1 protein (HMGB1),
a chromatin-binding protein that is released from cells during the
late stages of cell death induced by anthracyclines, oxaliplatin,
and ionizing irradiation. HMGB1 then interacts with TLR4 on the
surface of DCs and affects the intracellular fate of engulfed anti-
gen from dying tumor cells. Ligation of TLR4 by HMGB1 inhibits
the fusion of phagosomes (which contain antigenic cargo) with
lysosomes, thereby allowing the antigen to traffic toward the anti-
gen-presenting compartment (66). Neutralization or knockdown
of HMGB1 abolishes the capacity of dying tumor cells to elicit
antitumor immune responses, underscoring its contribution
to tumor immunogenicity (66). The aforementioned examples
illustrate that, depending on the cell death inducer, tumor cells
can expose or release factors that affect their uptake by DCs (e.g.,
CRT), the maturation of DCs (e.g., HSP90), or antigen presenta-
tion by DCs (e.g., HMGB1).

### Molecular and/or epidemiological evidence
### for an immune response during therapy

Pioneering work has highlighted a contribution of T cells to the
antitumor effects mediated by cytokotoxic agents (Tables 1 and 2)
(69). An EL4 thymoma cell clone that was relatively resistant to
the anthracycline doxorubicin in vitro gave rise to doxorubicin-sensi-
tive tumors when implanted into immunocompetent C57BL/6

### Table 1

<table>
<thead>
<tr>
<th>Tumor model</th>
<th>Description</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>L1210 leukemia</td>
<td>Chemoinmunotherapy combining IL-12 with cyclophosphamide, paclitaxel, or cisplatin does not ameliorate the effect of chemotherapy alone</td>
<td>100</td>
</tr>
<tr>
<td>Glasgow osteosarcoma</td>
<td>Camptothecin mediates T cell–independent antitumor effects</td>
<td>70</td>
</tr>
<tr>
<td>Pancreatic adenocarcinoma</td>
<td>Docetaxel mediates T cell–independent antitumor effects</td>
<td>70</td>
</tr>
<tr>
<td>MCA205 fibrosarcoma</td>
<td>X-rays are as efficient in immunocompetent mice as in nude mice</td>
<td>70</td>
</tr>
</tbody>
</table>
mice. This unexpected therapeutic effect, however, appeared to depend on splenocytes, suggesting that immunity could be indispensable to the antitumor effects mediated by anthracyclines (69). While this contention was not always supported by experimental data (Table 1), similar results have been obtained by other investigators in several other cancers (Table 2), provided that immunogenic chemotherapies (for example, anthracyclines or oxaliplatin) were administered. Thus, EL4 thymoma, Glasgow osteosarcomas, and CT26 colon cancer treated with oxaliplatin, as well as CT26 colon cancers and MCA205 fibrosarcomas treated with anthracyclines, exhibit much better therapeutic responses when the host is immunocompetent than when it is immunodeficient (e.g., athymic nude mice) (64, 66, 67, 70). Similarly, the depletion of CD4+ or CD8+ T cells by injection of specific monoclonal antibodies compromises the therapeutic efficacy of doxorubicin on CT26 tumors (64). TS/A, a cell line derived from a spontaneous mammary adenocarcinoma in BALB/c mice, also responded much better to local radiotherapy in immunocompetent as compared with athymic hosts (66). Together, these results demonstrate that the efficacy of chemotherapy and radiotherapy is influenced by the immune system.

The aforementioned results suggest that induction of immunogenic tumor cell death by anthracyclines, oxaliplatin, or ionizing radiation stimulates an immune response that helps keep the tumor in check. If this speculation were true, one would expect that tumor-derived proteins such as CRT and HMGB1 (which dictate the immunogenicity of tumor cell death) and the presence of their receptors on antigen-presenting cells would be required for full therapeutic success. Accordingly, the knockout of TLR4 and that of its dominant-negative fashion (66, 70). A clinical study indicated that breast cancer patients that carry the Asp299Gly TLR4 allele do not

### Table 2

<table>
<thead>
<tr>
<th>Tumor model</th>
<th>Description</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB1 mesothelioma</td>
<td>Gemcitabine and CD40 ligation promote synergistic CD8+ T cell–dependent antitumor effects</td>
<td>101</td>
</tr>
<tr>
<td>Meth A fibrosarcoma</td>
<td>The adoptive transfer of splenocytes from a host treated with cyclophosphamide promotes tumor regression</td>
<td>102</td>
</tr>
<tr>
<td>EL4 thymoma</td>
<td>Doxorubicin mediates antitumor effects in immunocompetent hosts bearing a doxorubicin-resistant tumor</td>
<td>69</td>
</tr>
<tr>
<td></td>
<td>TNF-α administration enhances doxorubicin-mediated antitumor effects</td>
<td>103</td>
</tr>
<tr>
<td>B16F10 melanoma</td>
<td>Tumors refractory to IM in vitro were sensitive to the same drug in vivo via the contribution of NK1.1+ cells</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>OM-174 (TLR agonist) and cyclophosphamide demonstrate a synergistic antitumor effect in vivo</td>
<td>104</td>
</tr>
<tr>
<td></td>
<td>Adoptive transfer of memory T cells synergizes with cyclophosphamide</td>
<td>105</td>
</tr>
<tr>
<td>CT26 colon cancer</td>
<td>Doxorubicin is more efficient in immunocompetent than athymic nude mice</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>Combination of DCs and TLR9 agonists with 5-FU and/or irinotecan decreases adverse events and</td>
<td>106</td>
</tr>
<tr>
<td></td>
<td>enhances antitumor effects</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Type 1 IFN and IL-2 boost etoposide- or cisplatin-mediated therapeutic effects</td>
<td>107</td>
</tr>
<tr>
<td>TS/A breast cancer</td>
<td>X-rays are more efficient in immunocompetent than athymic nude mice</td>
<td>66</td>
</tr>
<tr>
<td>Glasgow osteosarcoma</td>
<td>Oxaliplatin is more efficient in immunocompetent mice than athymic nude mice</td>
<td>66</td>
</tr>
<tr>
<td>Lymphocytic leukemia P288</td>
<td>The efficacy of doxorubicin is dependent on the radiosensitive cells of the host</td>
<td>108</td>
</tr>
<tr>
<td>Transgenic adenocarcinoma of mouse prostate (TRAMP) model</td>
<td>Imunosuppression compromises the efficacy of low electric field–enhanced chemotherapy</td>
<td>109</td>
</tr>
<tr>
<td>3LL Lewis lung carcinoma</td>
<td>Etoposide elicits long-term tumor-specific memory immune responses</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td>Cyclophosphamide efficacy is greatly enhanced by adoptive transfer of activated CD4+ T cells</td>
<td>111</td>
</tr>
<tr>
<td></td>
<td>Thymosin α1 combined with type 1 IFN enhances cyclophosphamide-mediated antitumor effects</td>
<td>112</td>
</tr>
<tr>
<td></td>
<td>Thymic humoral factor/2 combined with either melphalan or 5-FU prolonged survival</td>
<td>113</td>
</tr>
<tr>
<td>MOPC-315</td>
<td>Depletion of CD8+ T cells in tumor-bearing mice treated with low doses of melphalan abolished the curative effects of chemotherapy</td>
<td>114</td>
</tr>
<tr>
<td>76-9 rhabdomyosarcoma</td>
<td>IL-15 prolongs time to progression induced by cyclophosphamide through NK cells</td>
<td>115</td>
</tr>
<tr>
<td>Carcinoma H-N9</td>
<td>The efficacy of 5-FU and leucovorin in the treatment of hepatic metastases can be significantly augmented</td>
<td>116</td>
</tr>
<tr>
<td></td>
<td>by the addition of the liposome-encapsulated immunoadjuvant</td>
<td></td>
</tr>
<tr>
<td>BAMC-1 fibrosarcoma cells</td>
<td>Cyclophosphamide, epirubicin, and DWA2114R along with OK-432, G-CSF, and IL-2 allow T cell–dependent</td>
<td>117</td>
</tr>
<tr>
<td></td>
<td>tumor regression</td>
<td></td>
</tr>
<tr>
<td>Friend erythroleukemia cells (FLCs)</td>
<td>Thymosin α1 combined with low doses of IL-2 or type 1 IFN improves the efficacy of cyclophosphamide</td>
<td>118</td>
</tr>
<tr>
<td>L1210 leukemia</td>
<td>Effective chemoinmunotherapy of tumors using IL-12 combined with doxorubicin or mitoxantrone</td>
<td>100, 119</td>
</tr>
</tbody>
</table>
differ from patients displaying the normal TLR4 allele for any of the classical prognostic factors. However, the Kaplan-Meier estimate of metastasis-free survival after local radiotherapy and systemic anthracycline chemotherapy indicated that the Asp299Gly TLR4 allele (but not the TLR4 mutation, RefSNP identification number rs1927911) is an independent predictive factor of early relapse (66, 70). In metastatic renal cancer, a polymorphism in the IL-4 promoter strongly influences prognosis (73).

Many investigators use the term *immunochemotherapy* to describe the therapeutic instillation of monoclonal antibodies that recognize tumor antigens. Of note, the efficacy of immunochemotherapy in rituximab (anti-CD20)–treated follicular lymphoma is, in part, dictated by the efficacy of antibody-dependent cellular cytotoxicity, as determined by the Fc receptor IIIA genotype (74, 75) and the content of tumor-associated macrophages (76).

For technical reasons, there are very few studies that address the frequency of tumor-specific effector or memory T cells or antibody titers before and after chemotherapy. In infants with acute myeloid leukemia (AML), the emergence of antileukemia precursors after chemotherapy correlates with the maintenance of hematologic remission (77). Recently, a dynamic immunomonitoring study reported the presence of leukemia-specific, TNF-α–producing CD4+ T cells in patients bearing chronic myelogenous leukemia and successfully treated with IM (78). Spontaneous and induced T cell reactivities were associated with hematological and cytogenetic responses in a majority of patients. Interestingly, antibody titers against antiphospholipids were associated with prolonged survival after retinoic acid treatment in promyelocytic leukemia (79, 80). Galanis et al. studied the prognostic value of neuronal autoantibodies in small cell lung carcinoma patients. Although the titers of the paraneoplastic autoantibodies were associated with less-extensive disease at presentation, the cisplatin-based chemotherapy caused patients to become immunocompromised, and time to progression could not be predicted according to a rise in the antibody titers (81).

Future investigation should address the question, In which cancers does the induction of specific antitumor immune responses by immunogenic chemotherapies or radiotherapy have a prognostic impact?

**Immuonochemotherapy**

Based on the aforementioned premises, oncologists and immunotherapy experts might discuss the opportunity to optimize their current anticancer approaches. Such an optimization might stem
from the sequential strategy depicted in Figure 2, associating: (a) suppressors of tolerogenic pathways; (b) priming of naive T and B cells with vaccines; (c) induction of cell death with cytotoxic drugs; (d) agents rendering nonimmunogenic cell death immunogenic; (e) chloroquine (to combat host defects in TLR4 or block autophagy and multidrug resistance); (f) and sustaining immune effectors with NK, NKT, or DC adjuvants (e.g., TLR agonists, glycolipids, cytokines, chemokines).

Future studies should focus on combination therapies and determine the optimal schedule of chemoimmunomodulation, since the kinetics of the host and tumor response are likely critical determinants of the therapeutic response. Moreover, such combinations, while potentially effective, might also be fraught with significant toxicity (i.e., infectious diseases or autoimmunity, as have already been observed with the use of lymphodepletion or anti-CTLA4 antibodies). Phase I trials of immunotherapy may help define the toxicity and the dosage at which an immune response is achieved, but sizeable randomized studies will be needed to evaluate the optimal schedule of such therapeutic combinations.

To date, very few clinical studies have combined conventional chemotherapies with antigenic vaccination and/or immunostimulatory regimens (Table 3). In particular, there is no systematic or randomized assessment of the order in which cytotoxic therapies and tumor vaccines should be administered. In one trial, 29 end-stage non–small cell lung cancer patients who were resistant to first-line platin-based therapy were enrolled in a study employing a vaccination protocol involving autologous DCs infected with adenoviral vectors encoding p53 (82). Since the tumor progressed in 23 of 29 patients, salvage chemotherapy by paclitaxel or carboplatin was proposed as a second line of chemotherapy. The response rate to this second-line chemotherapy was 61.5%, and up to 38% survived at one year following vaccination. The historical controls were known to exhibit a 6%–16% objective response rate to a second-line chemotherapeutic, and less than 20% were alive beyond one year. A direct positive correlation between immune response to p53 and clinical outcome could be observed. Only 30% of patients who did not develop a p53-specific response to vaccination responded to second-line chemotherapy, whereas 75% of p53 cellular immune responders had objective clinical responses to chemotherapy after vaccination ($P = 0.08$) (82).

In another study, 17 patients bearing a diverse range of advanced tumors received an encapsulated DNA vaccine encoding the carcinogen activator cytochrome P450 1B1 expressed by almost all human tumors. While 10 of 11 who did not develop anti-CYP1B1–specific T cells failed to respond to salvage therapy, 5 of 6 who elicited immunity against CYP1B1 exhibited marked response to the salvage regimen for more than one year (83).

A similar conclusion was reached in a retrospective examination of the impact of vaccination based on peptide- or lysate-loaded DCs on the efficacy of conventional therapy (craniotherapy, stereotactic radiosurgery, radiotherapy, treatment with temozolomide alone or in combination with nitrosourea) against glioblastoma (84, 85). Progression rates and overall survival were compared among 12 tyrosinase-related protein 2–based (TRP-2–based) vaccine–treated patients, 13 chemotherapy-treated patients, and 13 glioblastoma patients treated with a combination of the TRP-2–

### Table 3

<table>
<thead>
<tr>
<th>Agents</th>
<th>Outcome</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Involving immunity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide, methotrexate, 5-FU (CMF regimen)</td>
<td>Corticosteroid-induced immunosuppression increases incidence of bone metastases in breast carcinoma</td>
<td>120</td>
</tr>
<tr>
<td>Not defined</td>
<td>Prior vaccination enhances response to subsequent therapy in immunological responders (phase I)</td>
<td>83</td>
</tr>
<tr>
<td>Platin, paclitaxel, or irinotecan</td>
<td>Correlation between immunological parameters and response to second-line chemotherapy in lung carcinoma</td>
<td>82</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>Randomized phase II testing of viral vaccine plus docetaxel versus vaccine alone in prostate cancer (outcome discussed in the main text)</td>
<td>89</td>
</tr>
<tr>
<td>Temozolomide</td>
<td>Vaccine sensitizes glioma to chemotherapy</td>
<td>85</td>
</tr>
<tr>
<td>Cisplatin and gemcitabine</td>
<td>Enhanced immune function in pancreatic carcinoma</td>
<td>121</td>
</tr>
<tr>
<td>Metronomic cyclophosphamide</td>
<td>Ablation of Tregs and restoration of immune responses in end-stage cancer patients; enhanced clinical responses to trastuzumab therapy in breast cancer</td>
<td>49, 122</td>
</tr>
<tr>
<td>IM</td>
<td>NK cell IFN-γ production in GIST patients has a prognostic impact on survival</td>
<td>54</td>
</tr>
<tr>
<td>Fludarabine and cyclophosphamide</td>
<td>Enhanced activity of adoptively transferred T cells after lymphodepletion induced by chemotherapy</td>
<td>23, 123</td>
</tr>
<tr>
<td>Gemcitabine, 5-FU, and oxaliplatin</td>
<td>Synergy with IL-2 and GM-CSF therapy in colon carcinoma</td>
<td>53</td>
</tr>
<tr>
<td><strong>Not involving immunity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinoic acid</td>
<td>Absence of synergy between chemotherapy and cytokine therapy in renal cell carcinoma</td>
<td>124</td>
</tr>
<tr>
<td>Fludarabine and cyclophosphamide</td>
<td>Absence of synergy with IL-2 in chronic lymphoid leukemia</td>
<td>125</td>
</tr>
<tr>
<td>VEGF trap</td>
<td>VEGF trap enhances blood DC maturation but not immune responses (phase I trial in metastatic cancer)</td>
<td>126</td>
</tr>
<tr>
<td>Cyclophosphamide, vincristine, and doxorubicin</td>
<td>Antiretroviral therapy and chemotherapy mediate tumor regression conditioned by tumor-related factors</td>
<td>127</td>
</tr>
<tr>
<td>Platin</td>
<td>Autoantibodies are associated with better disease outcome but not with platin-induced neuropathy or tumor regression</td>
<td>81</td>
</tr>
</tbody>
</table>

GIST, gastrointestinal stromal tumor.
based vaccine and chemotherapy. The results suggested that chemotherapysynergized with previous therapeutic vaccination to slow glioblastoma progression and significantly extend patient survival relative to individual therapies. In some cases, where the authors could establish glioblastoma cell lines before and after vaccination, the immunoselected tumor cells exhibited increased sensitivity to temozolomide and carboplatin compared with primary tumor cells. These data suggest that immunological targeting of TRP-2 increases sensitivity to cell death inducers (86).

Given the evidence of a role for testosterone in modulating B and T cell immune responses, there is a strong rationale for combining androgen deprivation with vaccine therapy in prostate cancer, and this is further supported by some experimental data (87). As reviewed by Aragon-Ching et al. (32), phase I and phase II trials indicated that androgen ablation may boost immune responses elicited by DCs, allogeneic prostate cancer cell lysate, or GM-CSF–secreting tumor cell–based vaccines (88). Arlen et al. (89) were the first to conduct a randomized study evaluating the use of vaccine alone versus concomitant vaccine plus weekly administration of docetaxel and steroids, with the end points of monitoring immune responses in 28 patients bearing a metastatic, androgen-resistant prostate cancer. First, they showed that a vaccine (admixed recombinant vaccinia virus expressing prostate-specific antigen [PSA]) or B7.1 followed by sequential boosts with fowlpox virus-PSA can be administered with weekly docetaxel and dexamethasone comedication without compromising the ability of the patient to mount tumor-associated antigen–specific T cell responses as compared with vaccine alone. They also evaluated clinical responses to the combination therapy, vaccine alone, and chemotherapy after progression following vaccination. Whereas progression-free survival in the combination arm was similar to that of the historical controls (median, 3.2 versus 3.7 months), there was an increase in progression-free survival in patients who received docetaxel following disease progression on vaccine alone (6.1 versus 3.7 months). Patients who crossed over to docetaxel following vaccination continued to maintain PSA-specific T cell responses that corresponded to declining serum levels of PSA. A similar trend was observed in a report by Noguchi et al., in which low-dose estramustine (a nitrogen mustard) was combined with HLA-A24–restricted peptide vaccination for prostate cancer. Combination therapy was associated with augmented CTL responses, peptide-specific IgG responses, and decreased serum levels of PSA in 13 patients (90).

The feasibility and safety of combining 5-FU–based chemotherapyswith carcinoembryonic antigen–derived (CEA-derived) peptides in adjuvants was evaluated in a study of 17 patients bearing colorectal cancer (91). Eight of 17 patients developed CEA-specific CTL responses, while 6 of 17 exhibited an objective response, a rate similar to that of historical controls treated with chemotherapy alone (91). A phase II trial enrolled 32 patients treated with anti-idiotype antibody mimicking the CEA antigen, with 14 of them additionally placed on a 5-FU–based regimen. All patients developed CEA-specific humoral and cellular immune responses (92). The 5-FU–based regimen, which is the standard of care for patients with localized colon cancer with nodal involvement, did not affect the immune response. These data warrant a phase III trial for patients with resected colon cancer.

Open questions in cancer immunology

Many clinical oncologists doubt the general impact of immune parameters on the practical management of neoplasia. How can clinical studies be designed in order to provide more ample evidence of the importance of cancer immunology?

It would be important to perform large-scale epidemiological studies that link the incidence and course of cancer—with therapeutic failure—to genotypic and phenotypic markers of immunodeficiency. As mentioned above, polymorphisms in the genes encoding TLR4 and cytokines may correlate with therapeutic outcome, but larger and more systematic studies (such as genome-wide SNP correlations) will be important in this area. It would be interesting as well to correlate the susceptibility to intracellular infectious agents (including viruses, listeria, tuberculosis, mycoplasma, etc.) with poor cancer chemotherapeutic responses. Moreover, an exhaustive meta-analysis should be performed on melanoma vaccination studies. Such a meta-analysis should address the putative positive impact of vaccination on later chemotherapeutic responses.

The prognostic impact of tumor-specific gene expression or proteomic profiles should be reinterpreted by studying markers of preexisting immune responses. The molecular profiling of follicular lymphoma at diagnosis indicated that the two gene-expression signatures that predicted survival comprised genes expressed by nonmalignant tumor-infiltrating cells, most likely myeloid and T cells. The nature of the infiltrating immune cells was the predominant feature of the cancer that predicted survival (93). It would be important to perform prospective trials in which serial tumor biopsies, performed before and after chemotherapy, are evaluated for signs of local immune responses as putative prognostic factors. If antitumor immune responses dictate long-term therapeutic success, then local signs of antigen-priming (i.e., the presence of DCs in a pseudolymphoid architecture and contexture) or T and NK cell responses (with the presence of effector memory T cells, preferentially of the Th1 type, that should outnumber Tregs) would correlate with favorable responses. This working hypothesis is supported by our recent data showing a correlation between pathological complete response to neoadjuvant chemotherapy and therapy-induced high CD8+ effector T lymphocyte and low Treg infiltrate levels in a series of 56 patients bearing locally advanced breast cancer (94).

The immunosuppressive side effects of massive chemotherapy should also be reevaluated. Although one cycle of lymphodepletion may constitute a therapeutic advantage due to homeostatic T cell repletion, repeated cycles of lymphodepletion may destroy the expanding population of tumor-specific immune effectors. For instance, in breast cancer, treatment with weak, repeated doses of anthracyclines (every week, ideally without glucocorticoids) should be compared with the usual therapeutic scheme in which intense doses are administered every three weeks (and usually accompanied by high doses of glucocorticoids to reduce the chemotherapy-associated discomfort) with simultaneous monitoring of tumor size (by PET/CT) and antitumor immune responses.

Along the same lines, it may be important to readdress the therapeutic management of different cancers, given the idea that chemotherapy should elicit an immune response. Hence, neoadjuvant chemotherapy (as opposed to adjuvant chemotherapy) of small cancers (such as early breast cancers discovered by routine radiographic screening) would offer the advantage that more tumor antigen would become available for the priming of T cells, while high-dose tolerance should not constitute a problem. Similarly, it could be important to preserve the sentinel lymph node rather than remove it systematically for disease staging purposes. Indeed,
the sentinel lymph node constitutes the privileged site of anti-
gen priming, in which the presence of activated DCs (expressing
DC-LAMP — a protein only expressed in mature DCs) constitutes
a positive prognostic marker, at least in melanoma (95).
Future studies might also include clinical trials to attempt to
correct the defective chemotherapeutic response of breast cancer
patients with the Asp299Gly TLR4 allele by administering chloro-
quine. Oral chloroquine is a widely used antimarial agent that acts
at an acceptable level of toxicity. In mice lacking TLR4, chloroquine
restores the chemotherapeutic response to oxalaplant, presumably
because it ameliorates deficient antigen presentation by DCs. In
TLR4-negative DCs, phagocytic cargo containing tumour antigen is
rapidly destroyed by lysosomes, and lysosomal inhibition by chloro-
quine restores antigen presentation. Similarly, chloroquine reestab-
ishes the defective presentation of dying tumor cell antigens by DCs
from patients carrying the Asp299Gly TLR4 allele in vitro (66).

From a biotechnological point of view, drug-screening approach-
es could be used to investigate the capacity of compounds to pro-
mote the translocation of CRT to the cell surface of a responding
cell line (selected on its response to anthracyclines for CRT expo-
sure). This screening could select druggable compounds based on
their capacity to induce immunogenic cell death (Figure 1).

In conclusion, we anticipate that clinical trials will corrobo-
rate the potential of assessing and eliciting antitumor immune
responses for prognostic and therapeutic purposes, provided that
of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J.
2000. Spontaneous regression of melanoma: a comparative study of TUNEL index and tumor-infiltrating lymphocytes between spontane-
2002. Development of antitumor immune respons-
es in reconstituted lymphopetitic hosts. Cancer Res.
2002. Different contributions of thymopoesis and homeo-
static-drive proliferation to the reconstruction of naive and memory T cell compartments. Proc. Natl.
29. Teague, R.M., et al. 2006. Interleukin-15 resuces toler-
ance CDB+ T cells for use in adoptive immunother-
Med. 12:1124–1125.
33. Drake, C.G., et al. 2005. Androgen ablation miti-
gates tolerance to a prostate/prostate cancer-
34. Roden, A.C., et al. 2004. Augmentation of T cell lev-
84:337–342.
Endocrinol. Metab. 290:E856–E863.

Address correspondence to: Laurence Zitvogel, INSERM U805, Institut Gustave Roussy, 39 rue Camille Desmoulins, F-94805 Villejuif, France. Phone: 33-1-42-11-60-41; Fax: 33-1-42-11-60-94; E-mail: zitvogel@igr.fr. Or to: Guido Kroemer, INSERM U848, Institut Gustave Roussy, Pavillon de Recherche 1, 39 rue Camille-
Desmoulins, F-94805 Villejuif, France. Phone: 33-1-42-11-60-46; Fax: 33-1-42-11-60-47; E-mail: kroemer@igr.fr.


